CIK 0001674416 · Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- operating
- EIN
- 473173478
- Phone
- 6173154600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,881,673
- in 7 filings, $1.5M under 10b5-1 plans
Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 60 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-12-22 | Bolzon Bradley J PhD Director | Sale | −26,016 | $20.30 | $528K | 27,724 |
| 2017-12-22 | Woiwode Thomas Director | Sale | −3,059 | $20.29 | $62K | 4,959 |
| 2017-12-21 | Kulkarni Samarth Chief Executive Officer | Option exercise | +15,000 | $1.81 | $27K | 148,560 |
| 2017-12-21 | Kulkarni Samarth Chief Executive Officer | Option exercise · Employee Stock Option (right to buy) | −15,000 | 279,558 | ||
| 2017-12-15 | Dylan-Hyde Tyler Chief Legal Officer | Sale | −15,000 | $18.90 | $283K | 130,204 |
| 2017-12-04 | CELGENE CORP /DE/ 10% owner | Sale | −30,485 | $19.47 | $594K | 3,722,534 |
| 2017-12-01 | Kulkarni Samarth Chief Executive Officer | Grant or award · Stock option (right to buy) | −75,000 | 75,000 | ||
| 2017-12-01 | CELGENE CORP /DE/ 10% owner | Sale | −87,991 | $19.10 | $1.7M | 3,753,019 |
| 2017-12-01 | Kulkarni Samarth Chief Executive Officer | Grant or award | +26,667 | $19.12 | $510K | 133,560 |
| 2017-12-01 | Kulkarni Samarth Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +260,000 | 260,000 | ||
| 2017-11-30 | CELGENE CORP /DE/ 10% owner | Sale | −12,666 | $19.04 | $241K | 3,841,010 |
| 2017-11-29 | CELGENE CORP /DE/ 10% owner | Sale | −4,263 | $19.25 | $82K | 3,853,676 |
| 2017-11-28 | CELGENE CORP /DE/ 10% owner | Sale | −5,080 | $19.22 | $98K | 3,857,939 |
| 2017-11-27 | CELGENE CORP /DE/ 10% owner | Sale | −27,990 | $19.75 | $553K | 3,863,019 |
| 2017-11-27 | Woiwode Thomas Director | Sale | −200 | $20.24 | $4K | 8,018 |
| 2017-11-27 | Bolzon Bradley J PhD Director | Sale | −200 | $20.24 | $4K | 53,740 |
| 2017-11-24 | CELGENE CORP /DE/ 10% owner | Sale | −26,010 | $20.00 | $520K | 3,891,009 |
| 2017-11-24 | Woiwode Thomas Director | Sale | −1,700 | $20.21 | $34K | 8,218 |
| 2017-11-24 | Bolzon Bradley J PhD Director | Sale | −1,507 | $20.21 | $30K | 53,940 |
| 2017-11-22 | CELGENE CORP /DE/ 10% owner | Sale | −256,000 | $19.76 | $5.1M | 3,917,019 |
Page 57 of 62 · 1,221 trades